Meet Moderna’s Most Likely Blockbusters After Its COVID Vaccine

1 min read

The FDA granted Moderna (NASDAQ: MRNA) an emergency use authorization for mRNA-1273 less than a week ago, and the COVID-19 vaccine is destined to rack up blockbuster sales within a matter of months. Based just on the supply deals the biotech already has in hand, mRNA-1273 should generate well over $13 billion next year. 

How much money mRNA-1273 will make after 2021 will depend in large part on how stiff the competition becomes as other coronavirus vaccines earn approval, and how frequently people need to be re-vaccinated. But Moderna won’t rest on its laurels after achieving this first success. Let’s meet the most likely blockbusters in Moderna’s pipeline now.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Red-Hot Stocks to Buy With Just $1,000

Next Story

American Airlines Shoots Itself in the Foot Again

Latest from Blog